BioMarin Pharmaceutical Inc. (BMRN)
NASDAQ: BMRN · Real-Time Price · USD
53.25
-0.30 (-0.56%)
May 14, 2026, 11:02 AM EDT - Market open
BioMarin Pharmaceutical Revenue
BioMarin Pharmaceutical had revenue of $766.21M in the quarter ending March 31, 2026, with 2.83% growth. This brings the company's revenue in the last twelve months to $3.24B, up 9.90% year-over-year. In the year 2025, BioMarin Pharmaceutical had annual revenue of $3.22B with 12.87% growth.
Revenue (ttm)
$3.24B
Revenue Growth
+9.90%
P/S Ratio
3.19
Revenue / Employee
$1,006,618
Employees
3,221
Market Cap
10.29B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.22B | 367.33M | 12.87% |
| Dec 31, 2024 | 2.85B | 434.69M | 17.97% |
| Dec 31, 2023 | 2.42B | 323.19M | 15.42% |
| Dec 31, 2022 | 2.10B | 249.76M | 13.53% |
| Dec 31, 2021 | 1.85B | -14.18M | -0.76% |
| Dec 31, 2020 | 1.86B | 156.41M | 9.18% |
| Dec 31, 2019 | 1.70B | 212.84M | 14.27% |
| Dec 31, 2018 | 1.49B | 177.56M | 13.52% |
| Dec 31, 2017 | 1.31B | 196.80M | 17.62% |
| Dec 31, 2016 | 1.12B | 226.96M | 25.50% |
| Dec 31, 2015 | 889.90M | 140.61M | 18.77% |
| Dec 31, 2014 | 749.28M | 200.80M | 36.61% |
| Dec 31, 2013 | 548.49M | 47.76M | 9.54% |
| Dec 31, 2012 | 500.72M | 59.37M | 13.45% |
| Dec 31, 2011 | 441.36M | 65.09M | 17.30% |
| Dec 31, 2010 | 376.27M | 51.61M | 15.90% |
| Dec 31, 2009 | 324.66M | 28.16M | 9.50% |
| Dec 31, 2008 | 296.49M | 172.82M | 139.74% |
| Dec 31, 2007 | 123.67M | 39.46M | 46.86% |
| Dec 31, 2006 | 84.21M | 58.54M | 228.06% |
| Dec 31, 2005 | 25.67M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Exelixis | 2.38B |
| Madrigal Pharmaceuticals | 1.13B |
| Ionis Pharmaceuticals | 1.06B |
| Axsome Therapeutics | 708.24M |
| Arrowhead Pharmaceuticals | 622.01M |
| Krystal Biotech | 417.30M |
| ImmunityBio | 140.98M |
| Cytokinetics | 105.82M |
BMRN News
- 3 days ago - BioMarin reinstated with a Neutral at Goldman Sachs - TheFly
- 6 days ago - BioMarin price target raised to $116 from $104 at Canaccord - TheFly
- 9 days ago - BioMarin price target lowered to $119 from $120 at Morgan Stanley - TheFly
- 9 days ago - BioMarin price target raised to $120 from $110 at Evercore ISI - TheFly
- 9 days ago - BioMarin price target lowered to $82 from $94 at Bernstein - TheFly
- 9 days ago - BioMarin Pharmaceutical Earnings Call Transcript: Q1 2026 - Transcripts
- 9 days ago - BioMarin Reports First Quarter 2026 Financial and Operating Results - PRNewsWire
- 10 days ago - BioMarin announces new research from studies of Voxzogo - TheFly